nach oben

Erschienen in:

19.08.2020 | Affective Disorder

Responsiveness to change over time and test-retest reliability of the PROMIS and Neuro-QoL mental health measures in persons with Huntington disease (HD)

verfasst von: Noelle E. Carlozzi, Nicholas R. Boileau, Matthew W. Roché, Rebecca E. Ready, Joel S. Perlmutter, Kelvin L. Chou, Stacey K. Barton, Michael K. McCormack, Julie C. Stout, David Cella, Jennifer A. Miner, Jane S. Paulsen

Erschienen in: Quality of Life Research | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

The majority of persons with Huntington disease (HD) experience mental health symptoms. Patient-reported outcome (PRO) measures are capable of capturing unobservable behaviors and feelings relating to mental health. The current study aimed to test the reliability and responsiveness to self-reported and clinician-rated change over time of Neuro-QoL and PROMIS mental health PROs over the course of a 24-month period.

Methods

At baseline, 12-months, and 24-months, 362 participants with premanifest or manifest HD completed the Neuro-QoL Depression computer adaptive test (CAT), PROMIS Depression short form (SF), Neuro-QoL Anxiety CAT, PROMIS Anxiety SF, PROMIS Anger CAT and SF, Neuro-QoL Emotional/Behavioral Dyscontrol CAT and SF, Neuro-QoL Positive Affect and Well-Being CAT and SF, and Neuro-QoL Stigma CAT and SF. Participants completed several clinician-administered measures at each time point, as well as several global ratings of change at 12- and 24-months. Reliability (test-retest reliability and measurement error) and responsiveness (using standardized response means and general linear models) were assessed.

Results

Test-retest reliability and measurement error were excellent for all PROs (all ICC ≥ .90 for test-retest reliability and all SEM percentages ≤ 6.82%). In addition, 12- and 24-month responsiveness were generally supported for the Neuro-QoL and PROMIS mental health PROs; findings relative to clinician-rated anchors of change (e.g., SRMs for the group with declines ranged from .38 to .91 for 24-month change and .09 to .45, with the majority above .25 for 12-month change) were generally more robust than those relative to self-reported anchors of change (e.g., SRMs for the group with declines ranged from .02 to .75, with the majority above .39 for 24-month change and .09 to .45, with the majority above .16 for 12-month change).

Conclusions

The Neuro-QoL and PROMIS mental health PROs demonstrated strong psychometric reliability, as well as responsiveness to self-reported and clinician-rated change over time in people with HD.

Nur mit Berechtigung zugänglich

Duff, K., et al. (2010). Mild cognitive impairment in prediagnosed Huntington disease. Neurology, 75(6), 500–507.PubMedPubMedCentral

Snowden, J., et al. (2001). Longitudinal evaluation of cognitive disorder in Huntington’s disease. Journal of the International Neuropsychological Society, 7(1), 33–44.PubMed

Paulsen, J. S., et al. (2001). Neuropsychiatric aspects of Huntington’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 71(3), 310–314.PubMedPubMedCentral

Duff, K., et al. (2007). Psychiatric symptoms in Huntington’s disease before diagnosis: the predict-HD study. Biological Psychiatry, 62(12), 1341–1346.PubMed

Long, J. D., et al. (2014). Tracking motor impairments in the progression of Huntington’s disease. Movement Disorders, 29(3), 311–319.PubMed

Maroof, D. A., Gross, A. L., & Brandt, J. (2011). Modeling longitudinal change in motor and cognitive processing speed in presymptomatic Huntington’s disease. Journal of Clinical and Experimental Neuropsychology, 33(8), 901–909.PubMed

Martinez-Horta, S., et al. (2016). Neuropsychiatric symptoms are very common in premanifest and early stage Huntington’s Disease. Parkinsonism & Related Disorders, 25C, 58–64.

Fisher, C. A., et al. (2014). Aggression in Huntington’s disease: A systematic review of rates of aggression and treatment methods. Journal of Huntington’s Disease, 3(4), 319–332.PubMed

van Duijn, E., et al. (2014). Neuropsychiatric symptoms in a European Huntington’s disease cohort (REGISTRY). Journal of Neurology, Neurosurgery and Psychiatry, 85(12), 1411–1418.PubMed

10.

Folstein, S., et al. (1983). The association of affective disorder with Huntington’s disease in a case series and in families. Psychological Medicine, 13(3), 537–542.PubMed

11.

Julien, C. L., et al. (2007). Psychiatric disorders in preclinical Huntington’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 78(9), 939–943.PubMed

12.

Shiwach, R. (1994). Psychopathology in Huntington’s disease patients. Acta Psychiatrica Scandinavica, 90(4), 241–246.PubMed

13.

Berrios, G. E., et al. (2002). Psychiatric symptoms in neurologically asymptomatic Huntington’s disease gene carriers: A comparison with gene negative at risk subjects. Acta Psychiatrica Scandinavica, 105(3), 224–230.PubMed

14.

van Duijn, E., Kingma, E. M., & van der Mast, R. C. (2007). Psychopathology in verified Huntington’s disease gene carriers. Journal of Neuropsychiatry and Clinical Neurosciences, 19(4), 441–448.

15.

Thompson, J. C., et al. (2012). Longitudinal evaluation of neuropsychiatric symptoms in Huntington’s disease. Journal of Neuropsychiatry and Clinical Neurosciences, 24(1), 53–60.

16.

Rosenblatt, A., & Leroi, I. (2000). Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics, 41(1), 24–30.PubMed

17.

Naarding, P., Kremer, H. P., & Zitman, F. G. (2001). Huntington’s disease: A review of the literature on prevalence and treatment of neuropsychiatric phenomena. European Psychiatry, 16(8), 439–445.PubMed

18.

Reedeker, W., et al. (2012). Psychiatric disorders in Huntington’s disease: A 2-year follow-up study. Psychosomatics, 53(3), 220–229.PubMed

19.

Reedeker, N., et al. (2012). Irritability in Huntington’s disease. Psychiatry Research, 200(2–3), 813–818.PubMed

20.

Codori, A. M., et al. (2004). Prevalence of major depression one year after predictive testing for Huntington’s disease. Genetics Testing, 8(2), 114–119.

21.

Naarding, P., et al. (2009). Apathy is not depression in Huntington’s disease. Journal of Neuropsychiatry and Clinical Neurosciences, 21(3), 266–270.

22.

De Souza, J., Jones, L. A., & Rickards, H. (2010). Validation of self-report depression rating scales in Huntington’s disease. Movement Disorders, 25(1), 91–96.PubMed

23.

Caine, E. D., et al. (1978). Huntington’s dementia. Clinical and neuropsychological features. Archives Of General Psychiatry, 35(3), 377–384.PubMed

24.

Pflanz, S., et al. (1991). The clinical manifestation of mental disorder in Huntington’s disease: A retrospective case record study of disease progression. Acta Psychiatrica Scandinavica, 83(1), 53–60.PubMed

25.

Carlozzi, N. E., & Ready, R. E. (2011). Health-related quality of life in Huntington’s disease. In C. Jenkinson, M. Peters, & M. B. Bromberg (Eds.), Quality of life measurement in neurodegenerative and related conditions. Cambridge: Cambridge University Press.

26.

van Duijn, E., et al. (2014). Course of irritability, depression and apathy in Huntington’s disease in relation to motor symptoms during a two-year follow-up period. Neurodegenerative Diseases, 13(1), 9–16.PubMed

27.

Carlozzi, N. E., et al. (2014). Understanding the outcomes measures used in huntington disease pharmacological trials: A systematic review. Journal of Huntington’s Disease, 3(3), 233–252.PubMedPubMedCentral

28.

FDA.GOV.

29.

Cella, D., et al. (2012). Neuro-QOL: Brief measures of health-related quality of life for clinical research in neurology. Neurology, 78, 1860–1867.PubMedPubMedCentral

30.

Cella, D., et al. (2011). The neurology quality of life measurement (Neuro-QOL) initiative. Archives of Physical Medicine and Rehabilitation, 92(Suppl 1), S28–S36.PubMedPubMedCentral

31.

Cella, D., et al. (2010). The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. Journal of Clinical Epidemiology, 63(11), 1179–1194.PubMedPubMedCentral

32.

Cella, D., et al. (2007). The patient-reported outcomes measurement information system (PROMIS): Progress of an NIH roadmap cooperative group during its first two years. Medical Care, 45(5 Suppl 1), S3–S11.PubMedPubMedCentral

33.

Carlozzi, N. E., & Tulsky, D. S. (2013). Identification of health-related quality of life (HRQOL) issues relevant to individuals with Huntington disease. J Health Psychol, 18(2), 212–225.PubMed

34.

Carlozzi, N. E., et al. (2019). Validation of Neuro-QoL and PROMIS mental health patient reported outcome measures in persons with Huntington disease (HD). Journal of Huntington’s Disease, 8(4), 467–482.PubMedPubMedCentral

35.

Carlozzi, N., et al. (2016). HDQLIFE: Development and assessment of health-related quality of life in Huntington disease (HD). Quality of Life Research, 25(10), 212–225.

36.

Hanauer, D. A., et al. (2015). Supporting information retrieval from electronic health records: A report of University of Michigan’s nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE). Journal of Biomedical Informatics, 55, 290–300.PubMedPubMedCentral

37.

Paulsen, J. S., et al. (2008). Detection of Huntington’s disease decades before diagnosis: The Predict-HD study. Journal of Neurology, Neurosurgery and Psychiatry, 79(8), 874–880.PubMed

38.

Gershon, R. C., et al. (2010). The use of PROMIS and assessment center to deliver patient-reported outcome measures in clinical research. J Appl Meas, 11(3), 304–314.PubMedPubMedCentral

39.

Magnus, B. E., et al. (2016). Mode effects between computer self-administration and telephone interviewer-administration of the PROMIS((R)) pediatric measures, self- and proxy report. Quality of Life Research, 25(7), 1655–1665.PubMedPubMedCentral

40.

Kisala, P. A., et al. (2019). Interviewer- versus self-administration of PROMIS(R) measures for adults with traumatic injury. Health Psychology, 38(5), 435–444.PubMedPubMedCentral

41.

Katz, P., et al. (2019). Psychometric evaluation of the national institutes of health patient-reported outcomes measurement information system in a multiracial, multiethnic systemic lupus erythematosus cohort. Arthritis Care & Research (Hoboken), 71(12), 1630–1639.

42.

Crins, M.H.P., et al. (2019). First validation of the full PROMIS pain interference and pain behavior item banks in patients with rheumatoid arthritis. Arthritis Care & Research (Hoboken).

43.

Katz, P., Pedro, S., & Michaud, K. (2017). Performance of the patient-reported outcomes measurement information system 29-item profile in rheumatoid arthritis, osteoarthritis, fibromyalgia, and systemic lupus erythematosus. Arthritis Care & Research (Hoboken), 69(9), 1312–1321.

44.

Jackson, W., & Novack, T. (1998). Effective serial measurement of cognitive orientation in rehabilitation: The Orientation Log. Archives of Physical Medicine and Rehabilitation, 79(6), 718–720.PubMed

45.

Gershon, R. C., et al. (2012). Neuro-QOL: quality of life item banks for adults with neurological disorders: Item development and calibrations based upon clinical and general population testing. Quality of Life Research, 21(3), 475–486.PubMed

46.

Perez, L., et al. (2007). Using focus groups to inform the Neuro-QOL measurement tool: Exploring patient-centered, health-related quality of life concepts across neurological conditions. Journal of Neuroscience Nursing, 39(6), 342–353.

47.

Cella, D., et al. (2011). The neurology quality-of-life measurement initiative. Archives of Physical Medicine and Rehabilitation., 92(10), S28–S36.PubMedPubMedCentral

48.

Cella, D., et al. (2012). Neuro-QOL brief measures of health-related quality of life for clinical research in neurology. Neurology, 78(23), 1860–1867.PubMedPubMedCentral

49.

Choi, S., et al. (2012) PROSetta® stone analysis report: A rosetta stone for patient reported outcomes (Vol. 1). Chicago, IL: Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University

50.

Carlozzi, N. E., et al. (2020). HDQLIFE and neuro-QoL physical function measures: Responsiveness in persons with huntington’s disease. Movement Disorders, 35(2), 326–336.PubMed

51.

Craufurd, D., Thompson, J. C., & Snowden, J. S. (2001). Behavioral changes in Huntington disease. Neuropsychiatry Neuropsychology and Behavioral Neurology, 14(4), 219–226.

52.

Cella, D., Hahn, E. A., & Dineen, K. (2002). Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening. Quality of Life Research, 11(3), 207–221.PubMed

53.

Huntington Study Group. (1996). Unified Huntington’s Disease Rating Scale: Reliability and consistency. Huntington Study Group. Movement Disorders, 11(2), 136–142.

54.

Shoulson, I., Kurlan, R., & Rubin, A. (1989). Assessment of functional capacity in neurodegenerative disorders: Huntington’s disease as a prototype. In T. Munsat (Ed.), Quantification of neurological deficits (pp. 285–309). Boston: Butterworth.

55.

Marder, K., et al. (2000). Rate of functional decline in Huntington’s disease. Neurology, 54(2), 452.PubMed

56.

Shoulson, I. (1981). Huntington disease: Functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology, 31, 1333–1335.PubMed

57.

Institute, S. A. S. (2013). SAS 9.4 language reference concepts. Cary, NC: SAS Institute.

58.

Cohen, J. (1969). Statistical power analysis for the behavioral sciences. New York: Academic Press.

59.

Jaescke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status: Ascertaining the minimal clinically important difference. Controlled Clinical Trials, 10, 407–415.

60.

King, M. T. (2011). A point of minimal important difference (MID): A critique of terminology and methods. Expert Review of Pharmacoeconomics & Outcomes Research, 11(2), 171–184.

61.

Wyrwich, K. W., Tierney, W. M., & Wolinsky, F. D. (1999). Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. Journal of Clinical Epidemiology, 52(9), 861–873.PubMed

62.

Flansbjer, U., et al. (2005). Reliability of gait performance tests in men and women with hemiparesis after stroke. Journal of Rehabilitation Medicine, 37, 75–82.PubMed

63.

Beaton, D. E., et al. (2001). Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome measures in rheumatology. Minimal clinically important difference. Journal of Rheumatology, 28(2), 400–405.

64.

Schmitt, J. S., & Di Fabio, R. P. (2004). Reliable change and minimum important difference (MID) proportions facilitated group responsiveness comparisons using individual threshold criteria. Journal of Clinical Epidemiology, 57(10), 1008–1018.PubMed

65.

Davidson, M., & Keating, J. L. (2002). A comparison of five low back disability questionnaires: Reliability and responsiveness. Physical Therapy, 82(1), 8–24.PubMed

66.

Goldie, P. A., Matyas, T. A., & Evans, O. M. (1996). Deficit and change in gait velocity during rehabilitation after stroke. Archives of Physical Medicine and Rehabilitation, 77(10), 1074–1082.PubMed

67.

de Boer, M. R., et al. (2005). Changes to the subscales of two vision-related quality of life questionnaires are proposed. Journal of Clinical Epidemiology, 58(12), 1260–1268.PubMed

68.

Cohen, J. (1992). A power primer. Psychological Bulletin, 112(1), 155–159.PubMed

69.

Kopjar, B. (1996). The SF-36 health survey: A valid measure of changes in health status after injury. Injury Prevention, 2, 135–139.PubMedPubMedCentral

70.

Dineen, K., et al. (2002). Meaningful change in cancer-specific quality-of-life scores: Differences between improvement and worsening. Clinical Therapeutics, 24, 41–42.

71.

Terwee, C. B., et al. (2007). Quality criteria were proposed for measurement properties of health status questionnaires. Journal of Clinical Epidemiology, 60(1), 34–42.PubMed

72.

Victorson, D., et al. (2014). Validity of the neurology quality-of-life (Neuro-QoL) measurement system in adult epilepsy. Epilepsy Behavior, 31, 77–84.PubMed

73.

Wohlfahrt, A., et al. (2019). Responsiveness of patient-reported outcomes measurement information system measures in rheumatoid arthritis patients starting or switching a disease-modifying antirheumatic drug. Arthritis Care & Research (Hoboken), 71(4), 521–529.

74.

Raad, M., et al. (2019). Validity and responsiveness of PROMIS in adult spinal deformity: The need for a self-image domain. Spine J, 19(1), 50–55.PubMed

75.

Hoth, K. F., et al. (2007). Patients with Huntington’s disease have impaired awareness of cognitive, emotional, and functional abilities. Journal of Clinical and Experimental Neuropsychology, 29(4), 365–376.PubMed

76.

Chatterjee, A., et al. (2005). A comparison of self-report and caregiver assessment of depression, apathy, and irritability in Huntington’s disease. Journal of Neuropsychiatry and Clinical Neurosciences, 17(3), 378–383.

77.

Duff, K., et al. (2010). “Frontal” behaviors before the diagnosis of Huntington’s disease and their relationship to markers of disease progression: Evidence of early lack of awareness. Journal of Neuropsychiatry and Clinical Neurosciences, 22(2), 196–207.

78.

Carlozzi, N. E., et al. (2018). Understanding patient-reported outcome measures in Huntington disease: At what point is cognitive impairment related to poor measurement reliability? Quality of Life Research, 27(10), 2541–2555.PubMedPubMedCentral

79.

Yost, K. J., et al. (2011). Minimally important differences were estimated for six patient-reported outcomes measurement information system-cancer scales in advanced-stage cancer patients. Journal of Clinical Epidemiology, 64(5), 507–516.PubMedPubMedCentral

80.

Lee, A. C., et al. (2017). Responsiveness and minimally important differences for 4 patient-reported outcomes measurement information system short forms: Physical function, pain interference, depression, and anxiety in knee osteoarthritis. The Journal of Pain, 18(9), 1096–1110.PubMedPubMedCentral

81.

Kazmers, N. H., et al. (2020). The minimal clinically important difference of the PROMIS and QuickDASH instruments in a nonshoulder hand and upper extremity patient population. The Journal of Hand Surgery. https://doi.org/10.1016/j.jhsa.2019.12.002.CrossRefPubMedPubMedCentral

82.

Kroenke, K., Baye, F., & Lourens, S. G. (2019). Comparative responsiveness and minimally important difference of common anxiety measures. Medical Care, 57(11), 890–897.PubMed

83.

Lapin, B., et al. (2019). Clinical utility of patient-reported outcome measurement information system domain scales. Circulation: Cardiovascular Quality and Outcomes, 12(1), e004753.

84.

Purvis, T. E., et al. (2018). Discriminant ability, concurrent validity, and responsiveness of PROMIS health domains among patients with lumbar degenerative disease undergoing decompression with or without arthrodesis. Phila PA: Spine.

85.

Khanna, D., et al. (2017). Responsiveness to change and minimally important differences of the patient-reported outcomes measurement information system gastrointestinal symptoms scales. Digestive Diseases and Sciences, 62(5), 1186–1192.PubMedPubMedCentral

86.

Amtmann, D., et al. (2016). Minimally important differences for patient reported outcomes measurement information system pain interference for individuals with back pain. Journal of Pain Reseach, 9, 251–255.

87.

Purvis, T. E., et al. (2017). Concurrent validity and responsiveness of PROMIS health domains among patients presenting for anterior cervical spine surgery. Spine, 42(23), E1357–E1365.PubMed

88.

89.

Mestre, T. A., et al. (2018). Quality of LIFE in Huntington’s disease: Critique and recommendations for measures assessing patient health-related quality of life and caregiver quality of life. Movement Disorders, 33(5), 742–749.PubMed

90.

Solomon, A. C., et al. (2007). Verbal episodic memory declines prior to diagnosis in Huntington’s disease. Neuropsychologia, 45(8), 1767–1776.PubMedPubMedCentral

91.

Tibben, A., et al. (1993). Presymptomatic DNA-testing for Huntington disease—pretest attitudes and expectations of applicants and their partners in the Dutch program. American Journal of Medical Genetics, 48(1), 10–16.PubMed

92.

Hocaoglu, M. B., Gaffan, E. A., & Ho, A. K. (2012). The Huntington’s disease health-related quality of life questionnaire (HDQoL): A disease-specific measure of health-related quality of life. Clinical Genetics, 81(2), 117–122.PubMedPubMedCentral

93.

Tabrizi, S. J., et al. (2012). Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: Analysis of 24 month observational data. Lancet Neurology, 11(1), 42–53.PubMed

94.

Marder, K., et al. (2000). Rate of functional decline in Huntington’s disease. Huntington Study Group. Neurology, 54(2), 452–458.PubMed

95.

Huntington Study Group, P.I., et al. (2016). Clinical-Genetic Associations in the prospective Huntington at risk observational study (PHAROS): Implications for clinical trials. JAMA Neurology, 73(1), 102–110.

96.

Nunnally, J., & Bernstein, I. (1994). Psychometric theory. New York: McGraw-Hill.

97.

Andresen, E. M. (2000). Criteria for assessing the tools of disability outcomes research. Archives of Physical Medicine and Rehabilitation, 81(12 Suppl 2), S15–S20.PubMed

98.

Cramer, D., & Howitt, D. L. (2004). The Sage dictionary of statistics.. Thousand Oaks, CA: Sage.

Titel: Responsiveness to change over time and test-retest reliability of the PROMIS and Neuro-QoL mental health measures in persons with Huntington disease (HD)
verfasst von: Noelle E. Carlozzi
Nicholas R. Boileau
Matthew W. Roché
Rebecca E. Ready
Joel S. Perlmutter
Kelvin L. Chou
Stacey K. Barton
Michael K. McCormack
Julie C. Stout
David Cella
Jennifer A. Miner
Jane S. Paulsen
Publikationsdatum: 19.08.2020
Verlag: Springer International Publishing
Schlagwörter: Affective Disorder
Affective Disorder
Anxiety
Erschienen in: Quality of Life Research / Ausgabe 12/2020
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-020-02596-1

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2020

Health-related quality of life in patients with non-functioning pituitary adenoma: a special focus on hydrocortisone replacement dose

An assessment of symptom burden in inflammatory bowel diseases to develop a patient preference-weighted symptom score

Six and eight weeks injection frequencies of bevacizumab are non-inferior to the current four weeks injection frequency for quality of life in neovascular age-related macular degeneration: a randomized controlled trial

Registered Reports: a process to safeguard high-quality evidence

Social cohesion and quality of life among survivors of a natural disaster

Registered Reports: response from the Chinese PRO SIG